Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg

This study has been terminated.
(during Period 1 due to numerous orthostatic AEs that occurred. Subsequently, RLD was reduced to 5 mg due to safety concerns.)
Sponsor:
Information provided by:
Mylan Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00647972
First received: March 30, 2008
Last updated: November 19, 2009
Last verified: November 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Primary Completion Date: May 2003 (Final data collection date for primary outcome measure)